LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (LXRX)

CUSIP: 528872302

Q1 2026 13F Holders as of 31 Mar 2026

Holder snapshot 7 signals
Share change
+62,911,525
Put/Call ratio
8.3%
SEC-reported price per share
$1.56
Number of holders
134
Value change
+$98,507,875
Number of buys
66
Open additional details 1 more signal available
Number of sells
41
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
442,581,578

Security key

528872302

Report period

Q1 2026

Institutions

134

Top holders

10

Ownership snapshot

Top reported holders of LXRX - LEXICON PHARMACEUTICALS, INC. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Siren, L.L.C.
Disclosed value leader
Artal Group S.A.
Comparable rows
0/15
Latest evidence
02 Feb 2026
3/4/5 13F Highest disclosed value: $156,607,553 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Artal Group S.A. has the largest disclosed position value at $156.61M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Artal Group S.A.'s linked filing trail.
Disclosed position value Top 5
Siren, L.L.C. $92.76M
Invus Global Management, LLC $25.86M
Invus US Partners LLC $6.09M
Avicenna Life Sci Master Fund LP $1.82M
Artal Group S.A. $156.61M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Siren, L.L.C.
3/4/5 13F
Director, 10%+ Owner · Individual
—
denominator unverified
$92,755,045
35,402,689 shares
— 25 Jul 2024
Invus Global Management, LLC
3/4/5
Director, 10%+ Owner
—
mixed-class rows
$25,864,432
1,905,607 shares
mixed-class rows
+$2,000,001 02 Feb 2026
Invus US Partners LLC
3/4/5
Director, 10%+ Owner
—
denominator unverified
$6,090,969
5,782,749 shares
— 05 Aug 2022
Avicenna Life Sci Master Fund LP
3/4/5
Director, 10%+ Owner
—
denominator unverified
$1,815,385
1,538,462 shares
— 02 Feb 2026
Artal Group S.A.
13F
Company
13F
—
denominator unverified
$156,607,553
136,180,481 shares
— 31 Dec 2025
FMR LLC
13F
Company
13F
—
denominator unverified
$43,509,338
37,834,207 shares
— 31 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
134
Shares
323,298,677
Rows available
134
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q1 2026 Across Filers

Q1 2026 holders
134
Q1 2026 holders
134
Holder diff
0
Investor Q1 2026 Shares Q1 2026 Shares Share Diff Share Chg % Q1 2026 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .